Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on June 8, 2020, reporting an event that occurred on June 2, 2020. The company is listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the termination of a material definitive agreement:
- Agreement Terminated: Amended and Restated Equity Distribution Agreement with A.G.P./Alliance Global Partners (AGP).
- Original Date: October 30, 2019 (amended January 29, 2020).
- Notice Date: June 2, 2020.
- Effective Termination Date: June 3, 2020.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the termination of the distribution agreement. The company noted that material terms of the terminated agreement were previously disclosed in 8-K filings from October 30, 2019, and January 29, 2020.
Investor Verification Checklist
- Verify the impact of terminating the AGP distribution agreement on the company's ability to raise capital via at-the-market offerings.
- Review the original Equity Distribution Agreement (filed as exhibits to prior 8-Ks) to understand any termination fees or obligations triggered by this action.
- Confirm if the company intends to enter into a new distribution agreement with AGP or another agent in the near future.